Pfizer’s MET097 Obesity Trial Reaches Key Milestone: What Investors Should Watch Next
Metsera, Inc. (MTSR) announced an update on their ongoing clinical study.
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The Phase 2b study VESPER-1, officially titled “A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of 28 Weeks to Investigate the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight Followed by a 32-Week Extension (VESPER-1),” evaluated once-weekly MET097 in adults with obesity or overweight. The goal was to measure weight loss and safety versus placebo, a key step in building a new obesity franchise for Pfizer and shaping expectations for future late-stage trials.
The trial tested MET097, an ultra-long-acting drug designed to mimic and enhance the body’s GLP-1 pathway, which plays a central role in appetite and weight control. MET097 was compared with a placebo saline injection to see if the active drug can deliver meaningful weight loss with a convenient once-weekly schedule and possibly less frequent dosing in the extension phase.
This was an interventional Phase 2b study with participants randomly assigned to either MET097 or placebo. The design was parallel-group and double-blind with four levels of masking, meaning patients, doctors, study staff, and outcome assessors did not know who received the drug, and the main purpose was to test weight-loss treatment rather than prevention or diagnosis.
The study first appeared in the registry on 27 November 2024, marking the formal start of public tracking for this program. The status is now listed as completed, and the last update was filed on 26 May 2026, signaling that key study activities have ended and that investors can look ahead to topline data and eventual posting of detailed results.
For investors, this completed Phase 2b study in obesity is important because GLP-1 drugs have transformed the weight-loss market and driven major gains for early leaders. A successful MET097 profile could boost sentiment for Pfizer (the lead sponsor) as it seeks to close the gap with incumbents, while any mixed or weak data may reinforce the competitive edge of current market leaders and pressure expectations for Pfizer’s broader metabolic pipeline.
The VESPER-1 study of MET097 is now completed and recently updated, and further details will be available on the ClinicalTrials portal as results are posted.
To learn more about MTSR’s potential, visit the Metsera, Inc. drug pipeline page.
